Axumin PET-CT for Brain Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
To learn if 18F-Fluciclovine (Axumin) PET-CT scans can be used to better detect brain metastatic lesions in patients who are receiving immunotherapy.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. It mentions that you must be on active immunotherapy, and other treatments are allowed as determined by your doctor.
Is 18F-Fluciclovine (Axumin) safe for use in humans?
How does Axumin PET-CT differ from other brain cancer treatments?
What data supports the effectiveness of the drug Axumin PET-CT for brain cancer?
Research shows that [18F]Fluciclovine (Axumin) has been effective in diagnosing brain tumors, especially where other methods have limitations. It has also been used successfully in detecting prostate and breast cancers, indicating its potential usefulness in identifying various types of cancer.23456
Who Is on the Research Team?
Yang Lu, MD
Principal Investigator
M.D. Anderson Cancer Center
Are You a Good Fit for This Trial?
Adults over 18 with brain metastases from cancer, currently on immunotherapy, can join this trial. They must be able to consent, have a life expectancy of at least 3 months, and be willing to undergo additional scans or biopsies if needed. Pregnant or breastfeeding individuals, those with severe allergies to Axumin PET radiopharmaceuticals, or conditions affecting study compliance are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Imaging
Participants undergo Axumin PET-CT scans to assess brain metastatic lesions
Follow-up
Participants are monitored for safety and effectiveness after imaging
What Are the Treatments Tested in This Trial?
Interventions
- 18F-Fluciclovine (Axumin)
- PET Scan
Find a Clinic Near You
Who Is Running the Clinical Trial?
M.D. Anderson Cancer Center
Lead Sponsor
Blue Earth Diagnostics
Industry Sponsor